With questions remaining regarding the potential safety and efficacy of agents inhibiting NF-κB and p38 signaling [53,57,58,59,60,61], our findings suggest that MAA and/or CIT might serve as novel ‘upstream’ therapeutic targets for mitigating cardiovascular complications in RA. Here, MAPK14 is linked to rheumatoid arthritis.